Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ProBioGen and ImmunOs extends their partnership for further large-scale manufacturing of clinical material for IOS-1002, a first-in-class, multi-functional agent based on a naturally occurring human leukocyte antigen, ImmunOs' lead program for the treatment of cancer.
Lead Product(s): IOS-1002,Pembrolizumab
Therapeutic Area: Oncology Product Name: IOS-1002
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: ProBioGen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 12, 2023
Details:
IOS-1002 is a first-in-class, multi-functional agent based on a naturally occurring human leukocyte antigen (HLA) that targets multiple immune checkpoints to activate both innate and adaptive immune cells, thereby leading to profound anti-tumor activity.
Lead Product(s): IOS-1002
Therapeutic Area: Oncology Product Name: IOS-1002
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
IOS-1002 is a first-in-class, multi-functional agent based on a naturally occurring human leukocyte antigen (HLA) that interacts with key components of the innate immune system and synergizes with the adaptive immune system, thereby leading to profound anti-tumor activity.
Lead Product(s): iosH2
Therapeutic Area: Oncology Product Name: IOS-1002
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021
Details:
The funds have been granted for the development of a pioneering HLA-open conformer-specific antibody to treat chronic inflammatory rheumatic diseases.
Lead Product(s): OCi mAb
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eurostars
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding April 13, 2021